ICON applies IBM Watson Clinical Trial Matching to Oncology Clinical Trials.
The companies have entered into an agreement to offer biotech and pharmaceutical clients access to ICON Laboratory Services’ global central laboratory experience combined with Cancer Genetic’s expertise in oncology testing and genomic assay development
New Firecrest Patient Portal, part of ICONIK Informatics Hub, designed to enhance patient engagement and support patient recruitment and retention.
Firecrest eConsent is a next-generation electronic informed consent solution that incorporates key recommendations from the FDA’s recent draft guidance on informed consent.
ICON is sponsoring a series of research projects, led by Professor Baruch Fischhoff, Ph.D., at Carnegie Mellon University (CMU), to find new ways to improve information comprehension and retention by clinical trial participants.